Previous 10 | Next 10 |
BASKING RIDGE, N.J., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today anno...
Gainers: Artelo Biosciences (ARTL) +93%. ImmunoGen (IMGN) +29%. Prothena Corporation (PRTA) +26%. NantKwest (NK) +21%. Illumina (ILMN) +19%.Losers: Amicus Therapeutics (FOLD) -33%. CollPlant Biotechnologies (CLGN) -30%. Caladrius Biosciences (CLBS) -20%. Conformis (CFMS) -16%. SQZ Biotechnolo...
Gainers: Artelo Biosciences (ARTL) +82%.Wunong Net Technology Company (WNW) +72%.China Liberal Education Holdings (CLEU) +53%.ION Geophysical (IO) +42%.Top Ships (TOPS) +42%.Seanergy Maritime Holdings (SHIP) +34%.Luokung Technology (LKCO) +29%.ImmunoGen (IMGN) +29%.EuroDry (EDRY) +28%.Lizhi (...
Caladrius Biosciences (CLBS) announced that it has entered into securities purchase agreements with several institutional investors to purchase an aggregate of 24.9M shares at a purchase price of $2.45 per share, with gross proceeds from the offerings expected to be about $65M.Caladrius ...
BASKING RIDGE, N.J., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today anno...
Are Biotech Penny Stocks Part Of Your Strategy In 2021? It’s February 2021, and the markets are at all-time highs. Trading volumes remain strong, and penny stocks continue captivating retail traders. We also see several hot industries fanning the flames of this market rally. ...
Gainers: Ocugen OCGN +127%, CRH Medical CRHM +80%, Nemaura Medical NMRD +44%, aTyr Pharma (LIFE) +44%, Veru VERU +34%.Losers: ERYTECH Pharma ERYP -16%, Panbela Therapeutics (PBLA) -10%, Progenity PROG -9%, Ca...
Longeveron has filed proposed terms for a $25 million IPO. The firm is developing a treatment for Alzheimer's Disease and other age-related conditions. LGVN is thinly capitalized and has scant chance of an AD treatment where major pharmas have failed, so I'll pass on the IPO. ...
BASKING RIDGE, N.J., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today ...
BASKING RIDGE, N.J., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today...
News, Short Squeeze, Breakout and More Instantly...
Caladrius Biosciences Inc. Company Name:
CLBS Stock Symbol:
NASDAQ Market:
Caladrius Biosciences Inc. Website:
BASKING RIDGE, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), announced today that, based upon the final vote count certified by the independent inspector of elections for the annual meeting of ...
NEW YORK, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Life Sciences Virtual Investor Conference to be held on September 15 th . Individual investors, institutional ...
BASKING RIDGE, N.J., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, today announced tha...